Background illustration for clinical trials search

Pulmonary Fibrosis Clinical Trials

Browse 206 Pulmonary Fibrosis clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Explanted Lung Tissues With Pulmonary Fibrosis

for
Pulmonary Fibrosis
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT00515567

Recruiting

Exploring the Utility of Hyperpolarized 129Xe MRI in Healthy Volunteers and Patients With Lung Disease

for
Asthma, Chronic Obstructive Pulmonary Disease, Bronchiectasis,
Location: Hamilton
Sponsor: McMaster University

Sex: All

Age: 18 - 70+

Code: NCT03455686

Recruiting

A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.

for
Idiopathic Pulmonary Fibrosis (IPF)
Location: Sherbrooke, Saint-Charles-Borromee, Kingston, Ajax,
Sponsor: AstraZeneca

Sex: All

Age: 40+

Code: NCT07652658

Phase 2, Recruiting

Preliminary Evaluation of [68Ga]CBP8 in Healthy Individuals, Lung Cancer, and Idiopathic Pulmonary Fibrosis Patients

for
Pulmonary Fibrosis, Lung Cancer
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18 - 70+

Code: NCT03535545

Phase 1, Recruiting

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

for
Idiopathic Pulmonary Fibrosis (IPF)
Location: New Haven CT, New York NY, Chapel Hill NC, Weston FL,
Sponsor: Rein Therapeutics

Sex: All

Age: 40+

Code: NCT06968845

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

for
Progressive Pulmonary Fibrosis,
Location: New Haven CT, New York NY, Trois-Rivieres, Montreal,
Sponsor: Avalyn Pharma Inc.

Sex: All

Age: 18+

Code: NCT06951217

Phase 2, Recruiting

Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis

for
Fibrosis Lung
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 18+

Code: NCT06940427

Phase 2, Recruiting

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

for
Idiopathic Pulmonary Fibrosis (IPF)
Location: St. John's, Halifax, Sherbrooke, Trois-Rivieres,
Sponsor: Avalyn Pharma Inc.

Sex: All

Age: 40+

Code: NCT07194382

Phase 2, Recruiting

Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis

for
Idiopathic Pulmonary Fibrosis (IPF)
Location: Philadelphia PA, Winston-Salem NC, Orlando FL,
Sponsor: InSilico Medicine Hong Kong Limited

Sex: All

Age: 40+

Code: NCT05975983

Phase 2, Recruiting

Advanced Imaging for Pulmonary Fibrosis

for
Pulmonary Fibrosis
Location: Boston MA
Sponsor: Peter Caravan

Sex: All

Age: 18 - 70+

Code: NCT06532071

Phase 2, Recruiting

Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis

for
Hemoptysis, Haemoptysis, Lung Disease, Pneumonia, Tuberculosis,
Location: Sherbrooke
Sponsor: Université de Sherbrooke

Sex: All

Age: 18+

Code: NCT02913365

Recruiting

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

for
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis,
Location: Kansas City KS
Sponsor: Mario Castro, MD, MPH

Sex: All

Age: 3+

Code: NCT04624490

Phase 1, Recruiting

Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism

for
Pulmonary Embolism, Embolism, Embolism and Thrombosis,
Location: Ottawa
Sponsor: Drahomir Aujesky

Sex: All

Age: 18+

Code: NCT04263038

Recruiting

Cough Capture as a Portal Into the Lung

for
Lung Diseases, Lung Cancer, Lung Diseases, Obstructive,
Location: The Bronx NY
Sponsor: Albert Einstein College of Medicine

Sex: All

Age: 21+

Code: NCT05854563

Recruiting

A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)

for
Pulmonary Hypertension, Interstitial Lung Disease,
Location: Kissimmee FL, Louisville KY, Bend OR
Sponsor: Pulmovant, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07816185

Phase 3, Recruiting

Prospective, Observational Study of Wellinks Effect on COPD Hospital Readmissions

for
COPD, Respiratory Tract Disease,
Location: Hartford CT
Sponsor: Convexity Scientific Inc

Sex: All

Age: 18+

Code: NCT05330507

Recruiting

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

for
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis,
Location: Research Triangle Park NC
Sponsor: National Institute of Environmental Health Sciences (NIEHS)

Sex: All

Age: 18 - 70+

Code: NCT06325696

Phase 2, Recruiting

ILD-SARDs Registry and Biorepository

for
Interstitial Lung Disease, Systemic Autoimmune Disease,
Location: Montreal
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Sex: All

Age: 18+

Code: NCT05007340

Recruiting

A Study of the Natural Progression of Interstitial Lung Disease (ILD)

for
Interstitial Lung Diseases, Idiopathic Pulmonary Fibrosis,
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT00470327

Recruiting
New

Evaluation of the F&P Mask, US, 2026

for
Chronic Respiratory Conditions, Obstructive Sleep Apnea (OSA)
Location: St Louis MO
Sponsor: Fisher and Paykel Healthcare

Sex: All

Age: 22+

Code: NCT07826429

Recruiting

What are clinical trials for pulmonary fibrosis?

Clinical trials for pulmonary fibrosis are research studies used to evaluate new treatments, therapies, or diagnostic methods for pulmonary fibrosis, a group of lung diseases characterized by scarring and inflammation of lung tissue. Pulmonary fibrosis clinical trials aim to find more effective ways to manage the disease, improve symptoms, and enhance quality of life for patients living with the disease.

They may involve testing new drugs, biologics, or treatment combinations, as well as exploring novel approaches like gene therapy or stem cell therapy. Clinical trials for pulmonary fibrosis can also assess new diagnostic tools or methods to detect the disease earlier or monitor its progression more accurately.

Why are clinical trials for pulmonary fibrosis important?

Although pulmonary fibrosis is considered a rare disease, it is still thought that up to 58,000 new cases are established every year in the US. Hence, clinical research into the disease is highly important. Pulmonary fibrosis clinical trials are important for advancing the development of new and more effective treatments for people with the condition, who may currently have limited therapeutic options and impacted quality of life.

These clinical trials help researchers evaluate novel drugs, therapies, and interventions that may slow disease progression, reduce symptoms, or improve lung function. They also contribute to a better understanding of the mechanisms of pulmonary fibrosis and identify potential biomarkers for earlier diagnosis.

Types of pulmonary fibrosis clinical trials

Participation in a pulmonary fibrosis clinical trial

Who can participate in a clinical trial for pulmonary fibrosis

How to enroll in a pulmonary fibrosis clinical trial